| URL | https://www.fiercepharma.com/manufacturing/astella |
| Source | Fierce Pharma |
| Date Published | 06/09/2022 |
| Author Name | Joseph Keenan |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Astellas Pharma |
| Parent company | Astellas Pharma |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 20222 |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Sanford |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy |